Belzutifan + Pembrolizumab Reduces Recurrence in Kidney Cancer

The treatment landscape for advanced kidney cancer is shifting, with emerging data suggesting a combination therapy of belzutifan and pembrolizumab could become a new standard of care following surgery. Recent findings indicate that adding belzutifan to the standard adjuvant pembrolizumab regimen significantly reduces the risk of cancer recurrence or death in patients with resected clear cell renal cell carcinoma – the most common type of kidney cancer. This development is being described by some experts as “practice changing,” potentially offering a substantial benefit to high-risk patients.

Understanding Clear Cell Renal Cell Carcinoma and Current Treatment

Clear cell renal cell carcinoma (ccRCC) accounts for approximately 85-90% of all kidney cancer diagnoses. Surgery, specifically radical nephrectomy (removal of the kidney), is the primary treatment for localized ccRCC. However, even after successful surgery, a significant proportion of patients – particularly those with high-risk features like tumor size or involvement of the renal vein – face a substantial risk of the cancer returning. Adjuvant therapy, treatment given after surgery to reduce the risk of recurrence, is often considered for these high-risk patients. Pembrolizumab, an immunotherapy drug that helps the body’s immune system fight cancer, is currently the standard adjuvant therapy for ccRCC.

Immunotherapy works by blocking proteins that prevent the immune system from attacking cancer cells. Pembrolizumab specifically targets the PD-1 protein, effectively releasing the brakes on the immune response. While pembrolizumab has shown benefit, researchers are continually seeking ways to improve outcomes, leading to the investigation of combination therapies.

LITESPARK-022: The Trial Driving the Change

The data driving this potential shift in practice comes from the LITESPARK-022 trial. The results, presented recently, demonstrate a statistically significant improvement in disease-free survival (DFS) – the length of time patients live without the cancer returning – in patients who received belzutifan in addition to pembrolizumab after surgery. Oncology News Central reports that the combination boosted disease-free survival.

Belzutifan is a relatively new drug that targets hypoxia-inducible factor (HIF), a protein that plays a role in cancer growth and spread, particularly in ccRCC. By inhibiting HIF, belzutifan can unhurried tumor growth and potentially make cancer cells more vulnerable to immunotherapy. The LITESPARK-022 trial enrolled patients with high-risk ccRCC who had undergone surgery and were starting adjuvant pembrolizumab. Patients were randomly assigned to receive either pembrolizumab alone or pembrolizumab plus belzutifan. The primary endpoint of the trial was DFS, and the results showed a significant benefit for those receiving the combination therapy. Oncodaily provides an update on the trial.

What Does This Mean for Patients?

The findings from LITESPARK-022 suggest that adding belzutifan to adjuvant pembrolizumab could significantly reduce the risk of recurrence in high-risk ccRCC patients. However, it’s crucial to understand that this is a single trial, and further research is needed to confirm these findings. The benefit observed in the trial was a reduction in the risk of recurrence or death, but it’s important to note that this is a relative risk reduction. The absolute benefit – the actual difference in the percentage of patients who remain cancer-free – will depend on individual patient characteristics and risk factors.

Currently, belzutifan is approved by the FDA for the treatment of certain types of kidney cancer associated with Von Hippel-Lindau (VHL) disease. The LITESPARK-022 data may lead to an expansion of its approved uses to include adjuvant therapy for ccRCC. Patients should discuss the potential benefits and risks of this combination therapy with their oncologist to determine if it’s an appropriate treatment option for them.

Trial Limitations and Future Research

As with any clinical trial, LITESPARK-022 has limitations. The study population was carefully selected, and the results may not be generalizable to all patients with ccRCC. The follow-up period was relatively short, and longer-term data are needed to assess the durability of the benefit. ASCO Daily News highlights the DFS benefit observed in the trial. Future research will focus on identifying biomarkers that can predict which patients are most likely to benefit from this combination therapy and on exploring other potential combinations with belzutifan and pembrolizumab.

The Evolving Role of Adjuvant Therapy in Kidney Cancer

The potential approval of belzutifan in combination with pembrolizumab represents a significant step forward in the treatment of high-risk ccRCC. It underscores the growing importance of adjuvant therapy in improving outcomes for these patients. The development of new and more effective adjuvant strategies is an active area of research, with ongoing trials evaluating other immunotherapies, targeted therapies, and combinations thereof.

The process of incorporating these new findings into clinical practice will involve careful consideration by medical societies and regulatory agencies. Guidelines will likely be updated to reflect the new evidence, and oncologists will need to stay abreast of the latest developments to provide their patients with the best possible care.

What comes next: The data from LITESPARK-022 are expected to be submitted to regulatory agencies for review, potentially leading to an expanded approval of belzutifan for use in adjuvant therapy for ccRCC. Ongoing monitoring of patients enrolled in the trial will provide longer-term data on the durability of the benefit and potential long-term side effects. Further research is planned to identify biomarkers that can help personalize treatment decisions and optimize outcomes for patients with ccRCC.